SBIR/STTR Research Award
Stop The Bleed - Save the Warfighter! : Intramuscular Auto-Injector Delivery of Tranexamic Acid (TXA) on the Battlefield
Award amount
$1,249,908Program and phase
SBIR · Phase II – Direct to Phase IIAward year
2023Award details
- Awarding agency
- Department of Defense
- Branch
- Air Force
- Recipient company
- RX BANDZ, INC.
- Proposal award date
- 2023-02-10
- Contract end date
- 2024-11-10
- UEI
- DXRED7S6FVE9
- Solicitation number
- X23.4
- Topic code
- AFX234-DCSO2
Research abstract
Non-compressible hemorrhages are the leading cause of preventative deaths in the military. Tranexamic acid (TXA) is an injectable medication that has not only been proven to be highly effective in controlling non-compressible hemorrhages but also in redu
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Shelf-life Extension for Emergency Medication
- Continue, Expand, and Refine Research and Development of a Hydromorphone Autoinjector
- Extended Utilization of Lifesaving Medications via Autoinjector
- Auto Injector Administration of Ketamine for Critically Injured Airmen
- Life-Saving Mini Auto-Injector to Deliver Epinephrine
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- AeroISU: Real-time Visibility and Mission Readiness of Industrial Storage Units (ISU), Containers & other USAF Equipment
- Trans Astronautica’s Sutter Turn Key Observatory
- Quantum Secure Identification
- Low-Probability-of-Intercept Terahertz Communications for Air Force Applications
- Accrete Argonaut Sequential
Research funding history
12 SBIR/STTR records share this UEI (2020–2023). Reported award amounts total $6,990,569. Reported amounts are not federal obligations.
Phases: Phase I, Phase II – Direct to Phase II, Phase II
Agencies: Department of Defense